New hope for older lymphoma patients: antibody clears hidden cancer DNA

NCT ID NCT06828991

Recruiting now Disease control Sponsor: Danielle Wallace Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 31 times

Summary

This study is for people aged 70 and older with a type of blood cancer called diffuse large B-cell lymphoma. After initial chemotherapy, some patients still have tiny traces of cancer DNA in their blood, which raises the risk of the cancer coming back. Researchers are testing whether adding a targeted antibody drug, mosunetuzumab, can clear that DNA and improve disease control. About 40 participants will receive the drug, and doctors will monitor safety and daily function using a special geriatric assessment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Wilmot Cancer Institute
RECRUITING

Rochester, New York, 14642, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.

DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)